What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Evinacumab demonstrated a moderate benefit in lowering LDL-C levels, with a 49% reduction compared to placebo in the ELIPSE trial. However, the lack of direct comparison with lomitapide and uncertainties regarding long-term cardiovascular outcomes limit the strength of this evidence.
Does the economic case hold at the expected price? — Cost effectiveness
Evinacumab is considered cost-effective compared to lomitapide, with the committee concluding it is cost-saving despite uncertainties in the cost-effectiveness analysis for younger populations. The high unmet need in young patients supports its economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee noted that HoFH significantly affects quality of life due to early cardiovascular disease symptoms. While evinacumab may improve LDL-C levels, direct evidence on HRQoL improvements is limited, but the potential for better management of the condition suggests moderate gains.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Evinacumab has a favorable safety profile, with a lower incidence of treatment-related adverse events compared to placebo. The committee noted that lomitapide has significant gastrointestinal side effects, suggesting evinacumab may be better tolerated.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator for evinacumab is lomitapide, which is appropriate. However, the lack of direct head-to-head trials and reliance on indirect comparisons introduces some limitations in the evidence base.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included only a small number of young patients (2 in ELIPSE), raising concerns about the generalizability of the results to the broader population of patients with HoFH.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Evinacumab can be integrated into existing treatment pathways with minimal disruption, as it is administered as an infusion every four weeks, which may improve adherence compared to daily oral medications.
Are the wider system costs understood? — Resource Use and Cost Implications
The committee acknowledged that while evinacumab is more expensive than standard LDL-C lowering therapies, it is expected to provide cost savings in the long term due to its effectiveness in managing HoFH.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily based on the Phase 3 ELIPSE trial, which is robust but has limitations due to the small sample size and lack of long-term outcome data. The committee recognized the need for further evidence to strengthen the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and cost-effectiveness of evinacumab, particularly in younger populations. The committee noted that these uncertainties could impact decision-making.
